Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Venet

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)Chiara Biagioni, Danai Fimereli, Alexandre Irrthum, et al.
Cancer Discovery|December 16, 2021
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast CancerChewei Anderson Chang, Jayu Jen, Shaowen Jiang, et al.
Nature Communications|November 4, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsMattia Rediti, Aranzazu Fernandez-Martinez, David Venet, et al.
Nature|August 2, 2023
Pharmacological targeting of netrin-1 inhibits EMT in cancerJustine Lengrand, Ievgenia Pastushenko, Sebastiaan Vanuytven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2Ariella B Hanker, Joan T Garrett, Mónica Valeria Estrada, et al.
Nature Communications|December 11, 2020
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cellsClara Gómez-Aleza, Bastien Nguyen, Guillermo Yoldi, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Cancer Discovery|June 29, 2021
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening InitiativePhilippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)Chiara Biagioni, Danai Fimereli, Alexandre Irrthum, et al.
Cancer Discovery|December 16, 2021
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast CancerChewei Anderson Chang, Jayu Jen, Shaowen Jiang, et al.
Nature Communications|November 4, 2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trialsMattia Rediti, Aranzazu Fernandez-Martinez, David Venet, et al.
Nature|August 2, 2023
Pharmacological targeting of netrin-1 inhibits EMT in cancerJustine Lengrand, Ievgenia Pastushenko, Sebastiaan Vanuytven, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2Ariella B Hanker, Joan T Garrett, Mónica Valeria Estrada, et al.
Nature Communications|December 11, 2020
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cellsClara Gómez-Aleza, Bastien Nguyen, Guillermo Yoldi, et al.
Nature Communications|November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trialLaurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Cancer Discovery|June 29, 2021
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening InitiativePhilippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, et al.
Pageof 5